J. Harenberg

J. Fareed, J. Harenberg, W. Jeske, 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Plasma hypercoagulability after termination of oral anticoagulants.

J. Harenberg, R. Zimmermann, R. Haas, 1983, Thrombosis research.

Collaborative study on monitoring methods to determine direct thrombin inhibitors lepirudin and argatroban

J. Harenberg, E. Gray, 2005, Journal of thrombosis and haemostasis : JTH.

Ximelagatran for Treatment and Prophylaxis of Recurrent Events in Deep Vein Thrombosis

J. Koscielny, H. Kiesewetter, J. Harenberg, 2007, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.

J. Harenberg, Jörg Ingrid, Fenyvesi Tivadar, 2002, The Israel Medical Association journal : IMAJ.

Impact of ABO blood groups on tirofiban mediated inhibition of platelet function

M. Feuring, M. Wehling, J. Harenberg, 2005, Platelets.

Magnetic bead protamine-linked microtiter assay for detection of heparin using iodinated low-molecular-mass heparin-tyramine.

G. Torri, B. Casu, J. Harenberg, 1995, Thrombosis research.

CHARACTERIZATION OF HEPARINS BY HIGH-PERFORMANCE SIZE EXCLUSION LIQUID CHROMATOGRAPHY

J. Harenberg, J. X. Vries, 1983 .

FIBRINOPEPTIDE A IN ACUTE CORONARY INSUFFICIENCY

J. Harenberg, E. Weber, R. Zimmermann, 1981, The Lancet.

Pharmacology of low molecular weight heparins.

J. Harenberg, 1990, Seminars in thrombosis and hemostasis.

Inhibition of low molecular weight heparin by protamine chloride in vivo.

A. Gnasso, J. D. de Vries, J. Harenberg, 1985, Thrombosis research.

Development of New Anticoagulants: Present and Future

J. Harenberg, Job Harenberg1, 2008, Seminars in thrombosis and hemostasis.

Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis.

N. Wimmer, E. Hammond, P. Handley, 2012, Journal of medicinal chemistry.

Determination of Dabigatran in Human Plasma Samples

J. Harenberg, S. Marx, R. Krämer, 2012, Seminars in Thrombosis & Hemostasis.

Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban

C. Weiss, S. Schulman, J. Harenberg, 2012, Journal of thrombosis and haemostasis : JTH.

Evaluation of smoking-induced effects on sympathetic, hemodynamic and metabolic variables with respect to plasma nicotine and COHb levels.

A. Horsch, J. Harenberg, E. Weber, 1979, Atherosclerosis.

Development of idraparinux and idrabiotaparinux for anticoagulant therapy

J. Harenberg, 2009, Thrombosis and Haemostasis.

Thrombin-antithrombin (TAT) complexes

J. Harenberg, 1999 .

22 Thrombin-antithrombin (TAT) complexes

J. Harenberg, 1999 .

Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancy.

J. Harenberg, 2007, Thrombosis research.

Treatment of heparin-induced thrombocytopenia with fondaparinux.

J. Harenberg, I. Jörg, T. Fenyvesi, 2004, Haematologica.

Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis

H. Polo Friz, C. Cimminiello, P. Prandoni, 2017, Internal and Emergency Medicine.

Anticoagulation in patients with impaired renal function and with haemodialysis Anticoagulant effects , efficacy , safety , therapeutic options

C. Weiss, M. Wehling, J. Harenberg, 2014 .

Performance Characteristics of DOAC Dipstick in Determining Direct Oral Anticoagulants in Urine

S. Hetjens, C. Weiss, J. Harenberg, 2021, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Is laboratory monitoring of low‐molecular‐weight heparin therapy necessary? Yes

J. Harenberg, 2004, Journal of thrombosis and haemostasis : JTH.

Measurement of Non–Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method

C. Weiss, M. Wehling, J. Harenberg, 2015, Therapeutic drug monitoring.

The Impact of Residual Thrombosis on the Long-Term Outcome of Patients with Deep Venous Thrombosis Treated with Conventional Anticoagulation

M. Prins, P. Prandoni, R. Pesavento, 2015, Seminars in Thrombosis & Hemostasis.

Anticoagulant treatment of COVID-19 as early as possible - Sulodexide and perspectives.

S. Schulman, J. Harenberg, 2021, Thrombosis and haemostasis.

Waves of SARS-CoV-2 Infection and Blood Coagulation—A Link and Beyond

F. Violi, J. Harenberg, 2021, Thrombosis and Haemostasis.

A Liaison between Sudden Sensorineural Hearing Loss and SARS-CoV-2 Infection

J. Jonas, J. Harenberg, E. Trecca, 2020, Thrombosis and Haemostasis.

Argatroban Treatment for Patients with Intoleranceto Heparin and Hirudin

J. Fareed, J. Harenberg, J. Walenga, 2005, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin.

J. Harenberg, U. Hoffmann, G. Huhle, 1999, Circulation.

Patients' Serum and Urine as Easily Accessible Samples for the Measurement of Non–Vitamin K Antagonist Oral Anticoagulants

C. Weiss, M. Wehling, J. Harenberg, 2015, Seminars in Thrombosis & Hemostasis.

Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH

C. Weiss, D. Hoppensteadt, J. Harenberg, 2014, Journal of thrombosis and haemostasis : JTH.

Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban

C. Weiss, J. Harenberg, S. Marx, 2011, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Arterial and Venous Thrombosis following Trauma and Major Orthopedic Surgery: Molecular Mechanisms and Strategies for Intervention

J. Harenberg, O. Dahl, K. Preissner, 2015, Seminars in Thrombosis & Hemostasis.

Long elimination half‐life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials

C. Weiss, G. Mikus, J. Harenberg, 2008, Journal of thrombosis and haemostasis : JTH.

DOAC Dipstick Testing Can Reliably Exclude the Presence of Clinically Relevant DOAC Concentrations in Circulation

S. Hetjens, J. Harenberg, D. Brkljačić, 2022, Thrombosis and haemostasis.

Anticoagulation in patients with impaired renal function and with haemodialysis. Anticoagulant effects, efficacy, safety, therapeutic options.

C. Weiss, M. Wehling, J. Harenberg, 2015, Hamostaseologie.

Performance of a Qualitative Point-of-Care Strip Test to Detect DOAC Exposure at the Emergency Department: A Cohort-Type Cross-Sectional Diagnostic Accuracy Study

B. Jilma, H. Herkner, A. Spiel, 2022, Thrombosis and haemostasis.

Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial

P. Verhamme, I. Ahrens, H. Darius, 2019, Thrombosis and Haemostasis.

Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability

C. Weiss, M. Wehling, J. Harenberg, 2011, Journal of Thrombosis and Thrombolysis.

Anticoagulant-related skin reactions

J. Harenberg, I. Jörg, T. Fenyvesi, 2002, Expert opinion on drug safety.

Concept of a point of care test to detect new oral anticoagulants in urine samples

C. Weiss, J. Harenberg, R. Krämer, 2013, Thrombosis Journal.

Determination of the anticoagulant effects of new oral anticoagulants: an unmet need

J. Harenberg, S. Marx, R. Krämer, 2012, Expert review of hematology.

Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women

M. Spannagl, J. Dudenhausen, C. Thaler, 2007, Thrombosis and Haemostasis.

Association of Changes in D-dimer and Other Coagulation Markers with Changes in Marder Score After Treatment of Acute Venous Thrombosis

M. Huisman, K. Merx, J. Harenberg, 2002, Journal of Thrombosis and Thrombolysis.

Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis.

K. Usadel, M. Blauth, K. Huck, 1990, Haemostasis.

Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor.

J. Harenberg, D. Heene, G. Weidinger, 1999, Thrombosis research.

A fluorescent probe assay (Heparin Red) for direct detection of heparins in human plasma

R. Krämer, J. Harenberg, E. Holmer, 2016, Analytical and Bioanalytical Chemistry.

Chapter 35 - Drugs affecting blood coagulation, fibrinolysis, and hemostasis

J. Harenberg, 2009 .

Treatment of a woman with lupus pernio, thrombosis and cutaneous intolerance to heparins using lepirudin during pregnancy.

C. Bayerl, C. Fiehn, J. Harenberg, 2005, Lupus.

Management of Heparin-Associated Thrombocytopenia in Pregnancy with Subcutaneous r-Hirudin

J. Harenberg, D. Heene, U. Hoffmann, 2000, Gynecologic and Obstetric Investigation.

Association of heparin‐induced skin lesions, intracutaneous tests, and heparin‐induced IgG

C. Bayerl, J. Harenberg, U. Hoffmann, 1999, Allergy.

Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women.

J. Harenberg, D. Schneider, L. Heilmann, 1993, Haemostasis.

Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low‐molecular‐weight heparin

J. Harenberg, D. Heene, H. Wolf, 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Detecting Anti-IIa and Anti-Xa Direct Oral Anticoagulant (DOAC) Agents in Urine using a DOAC Dipstick

S. Hetjens, C. Weiss, J. Harenberg, 2018, Seminars in Thrombosis and Hemostasis.

Acute cardiovascular reactions after cigarette smoking.

A. Horsch, J. Harenberg, E. Weber, 1980, Atherosclerosis.

Stability of the INR in Relation to Personality Traits in Patients On Stable Oral Anticoagulant Therapy.

L. Frölich, C. Weiss, J. Harenberg, 2009 .

Residual vein thrombosis and the risk of subsequent serious complications.

M. Prins, P. Prandoni, A. Lensing, 2015, Thrombosis research.

Fixed-dose versus adjusted-dose low molecular weight heparin for the initial treatment of patients with deep venous thrombosis

J. Harenberg, 2002, Current opinion in pulmonary medicine.

The injection of heparin prolongs the plasma clearance of oxidized low density lipoprotein in the rat.

A. Wunder, H. Schrenk, J. Harenberg, 1995, Thrombosis research.

Patients’ Plasma Activity of Heparin, low-Molecular-Weight Heparin or no Anticoagulants on Urine Based DOAC Test Strips

S. Hetjens, J. Harenberg, C. Weiss, 2022, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Identification of phenprocoumon metabolites in human urine by high-performance liquid chromatography and gas chromatography-mass spectrometry.

J. D. de Vries, J. Harenberg, R. Zimmermann, 1985, Journal of chromatography.

Pharmacology and special clinical applications of low‐molecular‐weight heparins

J. Harenberg, D. Heene, 1988, American journal of hematology.

Emerging concepts in thromboprophylaxis

J. Harenberg, 2002, Pathophysiology of Haemostasis and Thrombosis.

A new therapeutic option by subcutaneous recombinant hirudin in patients with heparin-induced thrombocytopenia type II: a pilot study.

V. Liebe, J. Harenberg, D. Heene, 2000, Thrombosis research.

Fibrinolytic Therapy of Deep Vein Thrombosis with Continuous Intravenous Infusion of a Recombinant Tissue Plasminogen Activator

C. Diehm, J. Harenberg, A. Horn, 1991, Seminars in thrombosis and hemostasis.

Differences of Present Recommendations and Guidelines for Generic Low-Molecular-Weight Heparins: Is There Room for Harmonization

J. Harenberg, 2011, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Overview on guidelines and recommendations for generic low-molecular-weight heparins.

J. Harenberg, 2011, Thrombosis research.

The effects of a combination of cigarette smoking and oral contraception on coagulation and fibrinolysis in human females

C. Staiger, J. Harenberg, E. Weber, 1985, Klinische Wochenschrift.

Fibrinopeptide A in human plasma--evaluation of a new radioimmunoassay technique on microliter--plates.

J. Harenberg, H. Schmidt‐Gayk, G. Hepp, 1979, Thrombosis research.

Bioequivalence of subcutaneous and intravenous body-weight-independent high-dose low-molecular-weight heparin Certoparin on anti-Xa, Heptest, and tissue factor pathway inhibitor activity in volunteers

M. Christ, M. Feuring, J. Harenberg, 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Bioavailability and antagonization of the low molecular weight heparin CY 216 in man.

J. Harenberg, R. Zimmermann, G. Schettler, 1986, Thrombosis research.

Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.

J. Harenberg, C. Giese, T. Fenyvesi, 2007, Seminars in thrombosis and hemostasis.

Purity of glycosaminoglycan‐related compounds using capillary electrophoresis

J. Harenberg, R. Malsch, 1996, Electrophoresis.

A fatal complication in a patient with heparin-induced thrombocytopenia type II re-exposed to heparin

J. Harenberg, D. Heene, U. Hoffmann, 1999, European Journal of Orthopaedic Surgery & Traumatology.

Low molecular weight heparins – Pharmacological principles and indications in clinical practice

J. Harenberg, 2000 .

Coagulopathy after snake bite byBothrops neuwiedi: Case report and results of in vitro experiments

C. Dempfle, J. Harenberg, D. Heene, 1990, Blut.

Urokinase therapy of subclavian-axillary vein thrombosis

P. Wahl, J. Harenberg, P. Gerhardt, 1981, Klinische Wochenschrift.

Lack of effect of cimetidine on action of phenprocoumon

C. Staiger, J. Harenberg, E. Weber, 1982, European Journal of Clinical Pharmacology.

Blood coagulation changes during effective thrombolysis using urokinase and heparin.

J. Harenberg, R. Zimmermann, H. Mörl, 1982, Thrombosis research.

Hepatic uptake of a modified low molecular weight heparin in rats.

A. Wunder, J. Harenberg, G. Stehle, 1992, The Journal of clinical investigation.

Increased phospholipase A activities in sera of intensive-care patients show sn-2 specificity but no acyl-chain selectivity.

K. van Ackern, J. Harenberg, J. Aufenanger, 1993, Clinical chemistry.

Development of a high-pressure liquid chromatography method for diagnosis of heparin-induced thrombocytopenia.

U. Budde, J. Harenberg, H. Schmidt‐Gayk, 2002, American journal of clinical pathology.

Microtiter assay for measurement of factor XIII activity in plasma.

C. Dempfle, J. Harenberg, D. Heene, 1992, The Journal of laboratory and clinical medicine.

Review of Pharmacodynamics, Pharmacokinetics, and Therapeutic Properties of Sulodexide

J. Harenberg, 1998 .

Biological Profile of the Hyper/Oversulfated Chondroitin Sulfate Contaminant Isolated from Recalled Heparin

R. Linhardt, J. Cunanan, D. Hoppensteadt, 2008 .

Asymptomatic and symptomatic deep venous thrombosis in hospitalized acutely ill medical patients: risk factors and therapeutic implications

Maria Felice Arezzo, C. Cogliati, D. Accapezzato, 2022, Thrombosis Journal.

Nephrology Dialysis Transplantation Monitoring of Heparins in Haemodialysis Using an Anti-factor-xa-specific Whole-blood Clotting Assay

J. Harenberg, G. Stehle, D. Heene, 2022 .

Monoclonal antibodies against heparin and heparinoids.

J. Harenberg, D. Heene, G. Huhle, 1997, Seminars in thrombosis and hemostasis.

Effect of single and multiple doses of sulphinpyrazone on antipyrine metabolism and urinary excretion of 6-beta-hydroxycortisol

U. Gundert-Remy, C. Staiger, J. Harenberg, 2004, European Journal of Clinical Pharmacology.

Detection and neutralisation of heparin by a fluorescent ruthenium compound

J. Harenberg, R. Krämer, Helga Szelke, 2009, Thrombosis and Haemostasis.

Interaction of heparin with cationic molecular probes: probe charge is a major determinant of binding stoichiometry and affinity.

R. Krämer, J. Harenberg, Helga Szelke, 2010, Bioorganic & medicinal chemistry letters.

Measurement of fluorescent-labeled LMM-heparin in biological fluids using protamine-linked microbeads.

J. Harenberg, D. Heene, L. Piazolo, 1997, Seminars in thrombosis and hemostasis.

Synthesis of a N'-alkylamine anticoagulant active low-molecular-mass heparin for radioactive and fluorescent labeling.

G. Torri, B. Casu, J. Harenberg, 1994, Analytical biochemistry.

Comparison of Three Heparin Bovine Serum Albumin Binding Methods for Production of Antiheparin Antibodies

J. Harenberg, D. Heene, G. Huhle, 1994, Seminars in thrombosis and hemostasis.

Semisynthesis and Analysis of Lipophilically Modified Unfractionated and Low Molecular Mass Heparins

G. Torri, B. Casu, J. Harenberg, 1994, Seminars in thrombosis and hemostasis.

Binding of fluorescent-labeled low molecular mass heparin to latex microspheres and to rat and human leukocytes.

J. Harenberg, D. Heene, L. Piazolo, 1994, Seminars in thrombosis and hemostasis.

Recommendations on biosimilar low‐molecular‐weight heparins

D. Bergqvist, S. Schulman, P. Mismetti, 2009, Journal of thrombosis and haemostasis : JTH.

Title Page / Table of Contents / Preface

F. Sofi, R. Abbate, P. Morange, 2003, Pathophysiology of Haemostasis and Thrombosis.

Anticoagulation in Patients with Heparin-Induced Thrombocytopenia Type II

J. Harenberg, D. Heene, G. Huhle, 1997, Seminars in thrombosis and hemostasis.

New Trends in Haemostasis

G. Schettler, J. Harenberg, G. Stehle, 1990, Veröffentlichungen aus der Geomedizinischen Forschungsstelle der Heidelberger Akademie der Wissenschaften.

Tissue factor pathway inhibitor in infants and children.

J. Harenberg, G. Weissbach, J. Wendisch, 1994, Thrombosis research.

Comparative Antithrombotic Potencies of Direct Thrombin Inhibitors and Low-Molecular-Weight Heparins in an Ex Vivo Human Experimental Thrombosis Model

J. Harenberg, I. Jörg, L. Piazolo, 2002, Seminars in thrombosis and hemostasis.

Monitoring of Anticoagulant Effects of Direct Thrombin Inhibitors

J. Harenberg, Tivadar Fenyvesi, Ingrid Jörg, 2002, Seminars in thrombosis and hemostasis.

Thrombelastometer and low molecular weight heparin

J. Harenberg, 2009, Anaesthesia.

Cutaneous Reactions to Anticoagulants

C. Bayerl, J. Harenberg, U. Hoffmann, 2001, American journal of clinical dermatology.

Influence of lepirudin, argatroban, and melagatran on prothrombin time and additional effect of oral anticoagulation.

J. Harenberg, T. Fenyvesi, I. Joerg, 2002, Clinical chemistry.

Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment

U. Gundert-Remy, C. Staiger, J. Harenberg, 2004, European Journal of Clinical Pharmacology.

COVID-19: progression of disease and intravascular coagulation – present status and future perspectives

E. Favaloro, J. Harenberg, 2020, Clinical chemistry and laboratory medicine.

Effect of dried garlic on blood coagulation, fibrinolysis, platelet aggregation and serum cholesterol levels in patients with hyperlipoproteinemia.

J. Harenberg, R. Zimmermann, C. Giese, 1988, Atherosclerosis.

High-resolution capillary electrophoresis and polycrylamide gel electrophoresis of heparins

J. Harenberg, D. Heene, R. Malsch, 1995 .

Low-molecular-weight heparin and dermatan sulfate end group-labeled with tyramine and fluorescein. Biochemical and biological characterization of the fluorescent-labeled heparin derivative.

G. Torri, B. Casu, J. Harenberg, 2002, Seminars in thrombosis and hemostasis.

Intact Biological Activity and Binding to Granulocytes of LMM-Heparin-Tyramine-Fitc

J. Harenberg, D. Heene, L. Piazolo, 1996 .

Determination of the anticoagulant phenprocoumon in human plasma and urine by high-performance liquid chromatography.

J. Harenberg, R. Zimmermann, M. Simón, 1982, Journal of chromatography.

Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth.

David M. Shackleford, T. Gonda, S. Charman, 2010, Journal of medicinal chemistry.

Hypercoagulability after immunotherapy with corynebacterium parvum in man

J. Harenberg, R. Zimmermann, D. Fritze, 1982, Blut.

Binding of Heparin to Human Leukocytes

J. Harenberg, D. Heene, L. Piazolo, 1994 .

Altered pharmacokinetic properties of a lipophilically derivatized low-molecular-weight heparin in rats.

A. Wunder, P. Peschke, H. Schrenk, 1993, The Journal of laboratory and clinical medicine.

Considerations about the Correct Nomenclature of Glycosaminoglycans (GAGs)

J. Harenberg, R. Malsch, 1993, Thrombosis and Haemostasis.

Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives.

J. Harenberg, R. Zimmermann, A. Knödler, 1989, Haemostasis.

Phenprocoumon metabolites in human plasma; characterization by HPLC and GC-MS

J. Harenberg, R. Zimmermann, J. Vries, 2004, European Journal of Clinical Pharmacology.

The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper

Yiannis A. Theodorou, J. Douketis, M. Dimopoulos, 2021, Thrombosis and Haemostasis.

Determination of heparin-induced IgG antibody by fluorescence-linked immunofiltration assay (FLIFA).

J. Harenberg, U. Hoffmann, G. Huhle, 1999, Journal of immunological methods.

Comparison of Two Different Ecarin Clotting Time Methods

C. Weiss, J. Harenberg, I. Jörg, 2005, Journal of Thrombosis and Thrombolysis.

Anti-Xa clotting activities in different hepatic-triglyceride lipase preparations from post-heparin plasma.

T. Barrowcliffe, J. Harenberg, J. Watton, 1991, Thrombosis research.

Biological Activrty and Safety of the Subcutaneous Administration of High Doses of Low Molecular Weight Heparin for 8 Days in Human Volunteers

J. Harenberg, G. Stehle, D. Heene, 1989, Thrombosis and Haemostasis.

Protamine Neutralization of the Release of Tissue Factor Pathway Inhibitor Activity by Heparins

J. Harenberg, G. Stehle, C. Dempfle, 1993, Thrombosis and Haemostasis.

Anticoagulant and lipolytic effects of a low molecular weight heparin fraction.

A. Gnasso, J. Harenberg, R. Zimmermann, 1985, Thrombosis research.

Nonanticoagulant Actions of Glycosaminoglycans

Job Harenberg, Benito Casu, B. Casu, 2011, Springer US.

Disposition of human fibrinopeptide A in normal and nephrectomized rabbits.

H. Hermann, M. Eisenhut, J. Harenberg, 1983, Thrombosis research.

Measurement of rivaroxaban and apixaban in serum samples of patients

C. Weiss, M. Wehling, G. Lip, 2014, European journal of clinical investigation.

Determination of Direct Oral Anticoagulants from Human Serum Samples

C. Weiss, J. Harenberg, A. Schulze, 2013, Seminars in Thrombosis & Hemostasis.

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

G. Lip, V. Marder, C. Weiss, 2012, International angiology : a journal of the International Union of Angiology.

Current and Future Prospects for Anticoagulant Therapy: Inhibitors of Factor Xa and Factor IIa

Martin Wehling, M. Wehling, J. Harenberg, 2008, Seminars in thrombosis and hemostasis.

New anticoagulants in atrial fibrillation.

J. Harenberg, 2009, Seminars in thrombosis and hemostasis.

Klinische Studien zu neuen direkten oralen Antikoagulanzien Clinical trials with new direct oral anticoagulants

C. Weiss, J. Harenberg, S. Marx, 2013, Phlebologie.

Development of a Tool to Identify Patients' Preference for Vitamin K Antagonist or Direct Oral Anticoagulant Therapy

C. Weiss, M. Wehling, L. Froelich, 2013, Seminars in Thrombosis & Hemostasis.

Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: What’s next?

M. Wehling, J. Harenberg, S. Marx, 2012, Thrombosis and Haemostasis.

New anticoagulants – promising and failed developments

M. Wehling, J. Harenberg, S. Marx, 2012, British journal of pharmacology.

Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin.

G. Schlierf, J. Harenberg, G. Stehle, 1993, Seminars in thrombosis and hemostasis.

Measurement of the new anticoagulants.

J. Harenberg, R. Kraemer, 2012, Thrombosis research.

Idraparinux and idrabiotaparinux

J. Harenberg, 2010, Expert review of clinical pharmacology.

Knowledge Gaps for Prophylactic Use of Antithrombotic Agents in Patients with COVID-19: Insights into New SARS-CoV-2 Variants, Vaccination Status, and Emerging Oral Antivirals

G. Lip, B. Bikdeli, J. Harenberg, 2022, Thrombosis and Haemostasis.

Acquired Autoimmune Hemophilia Following SARS-CoV-2 Vaccines: Dual-Drug Effects on Blood Coagulation and the Scylla and Charybdis Phenomenon

A. Falanga, J. Harenberg, M. Marchetti, 2021, Thrombosis and Haemostasis.

Tissue factor pathway inhibitor: proposed heparin recognition region

J. Harenberg, D. Heene, R. Malsch, 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Novel Methods for Assessing Oral Direct Factor Xa and Thrombin Inhibitors: Use of Point-of-Care Testing and Urine Samples

C. Weiss, J. Harenberg, A. Schulze, 2012, Seminars in Thrombosis & Hemostasis.

Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time.

C. Weiss, J. Harenberg, I. Jörg, 2003, Thrombosis research.

Effect of Thrombin Inhibitors and a Glycoprotein IIb/IIIa Receptor Antagonist in an Ex Vivo Human Experimental Thrombosis Model

J. Harenberg, L. Piazolo, K. Zokai, 2001, Seminars in thrombosis and hemostasis.

Influence of low molecular weight heparin on fibrin formation and platelet aggregation

J. Harenberg, R. Zimmermann, M. Schuler, 1985 .

Binding of Glycosaminoglycans to Leukocytes Using Fluorescent Labeled Gag-Derivatives

J. Harenberg, D. Heene, G. Huhle, 1996 .

[The intraindividual variation of fibrinolytic activity in volunteers (author's transl)].

J. Harenberg, E. Weber, E. Walter, 1978, Klinische Wochenschrift.

Measurement of Fibrinopeptide A in Patients Treated with Phenoprocoumon

J. Harenberg, R. Zimmermann, R. Haas, 1981, Thrombosis and Haemostasis.

Analysis of heparin binding to human leukocytes using a fluorescein-5-isothiocyanate labeled heparin fragment.

J. Harenberg, D. Heene, G. Huhle, 1996, Cytometry.

N' alkylamine low molecular mass heparins (LMM-heparin-tyramine and LMM-heparin-tyramine-fitc) exhibit long lasting anticoagulant effects.

J. Harenberg, D. Heene, L. Piazolo, 1995, Thrombosis research.

Is the diurnal increase of fibrinolytic activity influenced by alpha- or beta-adrenergic blockade ?

J. Harenberg, E. Weber, U. Spohr, 1980, Blut.

Re‐exposure to recombinant (r)‐hirudin in antihirudin antibody‐positive patients with a history of heparin‐induced thrombocytopenia

J. Harenberg, U. Hoffmann, G. Huhle, 2000, British journal of haematology.

The Dangerous Liaisons between Chronic Obstructive Pulmonary Disease and Venous Thromboembolism

P. Verhamme, J. Harenberg, 2020, Thrombosis and Haemostasis.

Prophylaxis of Thrombotic and Embolic Events in Acute Ischemic Stroke With the Low-Molecular-Weight Heparin Certoparin: Results of the PROTECT Trial

H. Diener, E. Ringelstein, I. Rektor, 2006, Stroke.

Partial in vivo neutralisation of plasma anticoagulant effects of Lomoparan (Org 10172) by protamine chloride.

J. T. ten Cate, H. ten Cate, T. van Dinther, 1991, Thrombosis research.

Heparins, Low-Molecular-Weight Heparins, and Other Glycosaminoglycans Analyzed by Agarose Gel Electrophoresis and Azure A-Silver Staining

J. Harenberg, R. Malsch, L. Wang, 1997, Seminars in thrombosis and hemostasis.

INTRAVENOUS IgG FOR PATIENTS WITH SPONTANEOUS INHIBITOR TO FACTOR VIII

B. Kommerell, W. Eich, K. Schimpf, 1985, The Lancet.

Effects of low‐molecular‐weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers

J. Harenberg, D. Heene, G. Huhle, 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Clinical and metabolic effects of gestodene and levonorgestrel.

M. Kohlmeier, T. Rabe, B. Runnebaum, 1987, International journal of fertility.

Monitoring of Heparin and Low Molecular Weight Heparin with Capillary and Venous Whole Blood

J. Harenberg, G. Stehle, D. Heene, 1988, Thrombosis and Haemostasis.

Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods

C. Weiss, M. Wehling, J. Harenberg, 2015, Clinical chemistry and laboratory medicine.

Effect of Phenprocoumon on Monitoring of Lepirudin, Argatroban, Melagatran and Unfractionated Heparin with the PiCT Method

J. Harenberg, T. Fenyvesi, I. Jörg, 2002, Pathophysiology of Haemostasis and Thrombosis.

Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.

J. Harenberg, 1987, Journal des Maladies Vasculaires.

Effects of vitamin K antagonist phenprocoumon on activated partial thromboplastin time measurement of direct thrombin inhibitors.

C. Weiss, J. Harenberg, I. Jörg, 2004 .

Effects of vitamin K antagonist phenprocoumon on activated partial thromboplastin time measurement of direct thrombin inhibitors

C. Weiss, J. Harenberg, I. Jörg, 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Quantitative determination of PEG-hirudin in human plasma using a competitive enzyme-linked immunosorbent assay.

J. Harenberg, G. Huhle, X. Song, 2000, Thrombosis research.

Capillary electrophoresis of r-hirudin and a polyethylene glycol derivative of r-hirudin (PEG-hirudin).

J. Harenberg, A. Timmermann, R. Malsch, 1997, Seminars in thrombosis and hemostasis.

Effects of a heparin-binding protein on blood coagulation and platelet function.

D. Hoppensteadt, J. Fareed, J. Harenberg, 2001, Seminars in thrombosis and hemostasis.

Monoclonal Antibody Directed Against Heparin and Heparin-Fractions

J. Harenberg, D. Heene, G. Huhle, 1996 .

Chromatographic and electrophoretic applications for the analysis of heparin and dermatan sulfate.

J. Harenberg, D. Heene, G. Huhle, 1996, Journal of chromatography. B, Biomedical applications.

Blood Coagulation , Fibrinolysis and Cellular Haemostasis 252 Fixed-dose , body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis

H. Riess, J. Harenberg, H. Siemens, 2003 .

Treatment of patients initially for acute deep vein thrombosis with a low‐molecular‐weight heparin at a fixed, body weight‐independent dosage

H. Riess, J. Harenberg, G. Weidinger, 2004, Journal of thrombosis and haemostasis : JTH.

Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.

M. Blauth, K. Huck, J. Harenberg, 1997, Seminars in thrombosis and hemostasis.

Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.

M. Huisman, J. Harenberg, H. Breddin, 2001, Seminars in thrombosis and hemostasis.

Comparative Human Pharmacology of Low Molecular Weight Heparins

J. Harenberg, G. Stehle, R. Zimmermann, 1989, Seminars in thrombosis and hemostasis.

Clinical trials with new oral anticoagulants

C. Weiss, J. Harenberg, C. Weiss, 2013, Hämostaseologie.

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany

M. Wehling, G. Lip, J. Harenberg, 2015, BioMed research international.

Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries

L. Frölich, M. Wehling, J. Harenberg, 2012, Journal of Thrombosis and Thrombolysis.

The Effect of Self-Monitoring the INR on Quality of Anticoagulation and Quality of Life

J. Harenberg, D. Heene, T. Wenzel, 1999, Seminars in thrombosis and hemostasis.

Risk assessment of venous thromboembolism in medical patients.

J. Harenberg, 2000, Seminars in hematology.

Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial.

G. Hommel, C. Kirkpatrick, J. Harenberg, 2000, International journal of oncology.

COVID-19 PANDEMIC UPDATES AND PERSPECTIVES. NEED FOR AN INTEGRATED AND EQUITABLE APPROACH.

V. Maréchal, A. Falanga, N. Jabeen, 2021, Thrombosis and haemostasis.

Treatment of digitalis intoxication with digoxin-specific Fab antibody fragments.

P. Wahl, C. Staiger, J. Harenberg, 1983, The New England journal of medicine.

Update of the recommendations on biosimilar low‐molecular‐weight heparins from the Scientific Subcommittee on Control of Anticoagulation of the International Society on Thrombosis and Haemostasis

J. Fareed, G. Torri, L. Drouet, 2013, Journal of thrombosis and haemostasis : JTH.

A consensus conference on complex biologics and low molecular weight heparins.

L. Ried, C. Carter, D. Hoppensteadt, 2010, International Angiology.

Multicentric evaluation of heparinase on aPTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factor

J. Hirsh, P. Rustagi, J. Harenberg, 1996, Blood Coagulation and Fibrinolysis.

Purification of the monoclonal heparin antibody H-1.18.

J. Harenberg, G. Huhle, R. Malsch, 1996, Journal of chromatography. A.

Comparison of the DOAC Dipstick Test on Urine Samples With Chromogenic Substrate Methods on Plasma Samples in Outpatients Treated With Direct Oral Anticoagulants

S. Hetjens, J. Fareed, I. Elalamy, 2023, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis – the membrane study

D. Krieter, H. Lemke, J. Harenberg, 2012, BMC Nephrology.

Inequivalence of Glycosaminoglycans Using High-Performance Size Exclusion Chromatography, Polyacrylamide Gel Electrophoresis and High-Performance Capillary Electrophoresis

J. Harenberg, D. Heene, L. Piazolo, 1996 .

Improved laboratory confirmation of heparin-induced thrombocytopenia type II. Time course of antibodies and combination of antigen and biologic assays.

M. Feuring, J. Harenberg, U. Hoffmann, 2001, American journal of clinical pathology.

Cimetidine does not increase the anticoagulant effect of phenprocoumon.

C. Staiger, J. Harenberg, E. Weber, 1982, British journal of clinical pharmacology.

[Anticoagulation in patients with heart valve replacement in pregnancy].

J. Harenberg, 1998, Zeitschrift fur Kardiologie.

Does Chronic Treatment with Oral Anticoagulants Ameliorate the Clinical Course of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Coronavirus Disease 2019 (COVID-19)?

W. Ageno, J. Harenberg, R. Bauersachs, 2020, Seminars in Thrombosis and Hemostasis.

[Treatment in a heparin-induced skin reaction with a low-molecular heparin analog].

J. Harenberg, E. Weber, R. Zimmermann, 2008, Deutsche medizinische Wochenschrift.

Past, present, and future perspectives of heparins in clinical settings and the role of impaired renal function.

J. Harenberg, 2016, International journal of cardiology.

The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients: a rebuttal

J. Harenberg, 2005, Journal of thrombosis and haemostasis : JTH.

[Heparin, thrombin and Factor Xa inhibitors].

J. Harenberg, T. Fenyvesi, 2004, Hamostaseologie.

Tissue factor pathway inhibitor: proposed heparin recognition region

J. Harenberg, D. Heene, R. Malsch, 1995, Blood Coagulation and Fibrinolysis.

The Use of Low Molecular Weight Heparin (LMWH) in Pregnancy

J. Harenberg, L. Heilmann, H. Breddin, 2022 .

Long term anticoagulation with low molecular weight heparin in outpatients with side effects on oral anticoagulants.

J. Harenberg, D. Heene, R. Zimmermann, 1989, Nouvelle revue francaise d'hematologie.

Clinical Pharmacologal Profile of Low Molecular Weight Heparins

J. Harenberg, 1990 .

Laboratory diagnosis of heparin-induced thrombocytopenia type II after clearance of platelet factor 4/heparin complex.

M. Feuring, J. Harenberg, U. Hoffmann, 2001, The Journal of laboratory and clinical medicine.

Pharmacokinetics of Certoparin During In Vitro and In Vivo Dialysis.

C. Wanner, D. Krieter, H. Lemke, 2015, Artificial organs.

Effects of Sized Heparin Oligosaccharide on the Interactions of Chinese Hamster Ovary Cell with Thrombospondin

P. Kaesberg, W. Ershler, J. Choay, 1992, Seminars in thrombosis and hemostasis.

Old and new risk factors for upper extremity deep venous thrombosis – a rebuttal

J. Harenberg, 2006, Journal of thrombosis and haemostasis : JTH.

Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban

S. Schulman, J. Harenberg, S. Marx, 2012, Journal of thrombosis and haemostasis : JTH.

Treatment of Deep Vein Thrombosis with Low-Molecular-Weight Heparins: A Consensus Statement of the Gesellschaft für Thrombose-und Hämostaseforschung (GTH)

U. Schmitz-Huebner, K. Breddin, J. Kienast, 1997, Seminars in thrombosis and hemostasis.

Competitive Binding of Low Molecular Mass Heparin-Tyramine Fluorescein-5-Isothiocyanate and Unlabeled Glycosaminoglycans to Leukocytes

J. Harenberg, L. Piazolo, R. Malsch, 1994, Seminars in thrombosis and hemostasis.

The Impact of Residual Thrombosis on the Long-Term Outcome of Patients with Deep Venous Thrombosis Treated with Conventional Anticoagulation

M. Prins, P. Prandoni, R. Pesavento, 2015, Seminars in Thrombosis & Hemostasis.

Measurement of Non–Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method

C. Weiss, M. Wehling, J. Harenberg, 2015, Therapeutic drug monitoring.

Detection of Direct Oral Anticoagulants in Patient Urine Samples by Prototype and Commercial Test Strips for DOACs – A Systematic Review and Meta-analysis

S. Hetjens, C. Weiss, M. Crowther, 2021, TH Open.